Tuberculous Pleurisy: The Role of the ADA Enzyme in Diagnosis and Treatment Outcomes

Abdugapparov F*, Mamatov L and Ongarbayev D

Department of Phthisiology and Pulmonology, Tashkent Medical Academy, Uzbekistan

^*Correspondance to: Fazlkhan Abdugapparov 

 PDF  Full Text Case Report | Open Access

Abstract:

Purpose: To study the role of the ADA enzyme in diagnosis and treatment outcomes. Methods: The study conducted here was a cohort study that relied on secondary data sourced from medical charts and TB forms of patients. Specifically, the study focused on individuals who were referred to the inpatient department of the Republican Specialized Scientific Practical Medical Center of Phthisiology and Pulmonology (RSSPMCPP) in Tashkent, Uzbekistan, between the years 2021 and 2022. Results: From 2021 to 2022, the pleural fluid and blood serum of 80 patients were examined in the clinics of the Republican Specialized Physiology and Pulmonology Scientific and Practical Medical Center and the Tashkent Clinical Hospital of Physiology and Pulmonology. All of them were divided into 2 groups - (1) with TP, (2) with pleurisy of non-TB etiology. Group 1 patients had higher ADA in pleural fluid and blood serum than those in group 2. It was observed that the amount of ADA in pleural fluid was 3.2 times higher in group 1 than in group 2 (46,6 to 14,4 respectively), and 5.5 times higher in blood serum (25,3 to 4,5 respectively), respectively. The majority of patients examined had a successful treatment outcome (n=50, 91%), which was more common among people aged 40 years and younger (90.9%) compared to the older group (89.2%), with differences there was practically nothing between them. Gender groups (90.4% and 87.5% among men and women, respectively). Age or gender was not significantly associated with the risk of poor treatment outcome. Six (8.7%) patients had evidence of resistance to at least rifampicin, and the presence of drug-resistant tuberculosis significantly increased the risk of treatment failure (RR 3.97; 95% CI: 1.13-13.93, P value 0.031). Hepatitis was the only comorbidity significantly associated with the risk of treatment failure (RR 4.8; 95% CI: 1.44-15.98, P value 0.011). Conclusion: Due to the varying sensitivity and specificity of different diagnostic approaches, the diagnosis of pleural effusion remains challenging. Multidisciplinary approaches

Keywords:

Tuberculosis; Pleural effusion; ADA; Diagnosis; Pleural fluid aspiration; Pleural biopsy; Treatment outcome

Cite the Article:

Abdugapparov F, Mamatov L, Ongarbayev D. Tuberculous Pleurisy: The Role of the ADA Enzyme in Diagnosis and Treatment Outcomes. Ann Clin Case Rep. 2024; 9: 2694..